We came across a bullish thesis on Intellia Therapeutics, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.’s share was trading at $12.48 as of February 18th.
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. NTLA represents a potentially transformative opportunity in the biotechnology space, anchored by its pioneering work in in-vivo CRISPR gene editing. The company is among the first to demonstrate systemic CRISPR efficacy in humans, targeting diseases like ATTR amyloidosis and hereditary angioedema, with one-time treatments that could replace chronic therapies.
If successful, this positions Intellia at the forefront of a new drug category—genomic surgery—validated by partnerships with major pharma players such as Regeneron, Novartis, and Vertex. While regulatory standards are still evolving and long-term safety remains unproven, the platform’s potential for expansion across multiple monogenic diseases offers enormous optionality.
Intellia’s market opportunity is significant, with ATTR and HAE representing multi-billion-dollar markets and pricing for one-time therapies expected between $500,000 and $2 million per patient. Gross margins for such therapies could exceed 80%, and the platform could eventually extend into oncology and CNS disorders.
The company has a strong balance sheet, typically maintaining over $700 million in cash, supported by partner funding, and a low-debt structure, providing a runway of 2–3 years without additional financing. Institutional backing is robust, with major biotech funds and Regeneron holding significant stakes, although volatility in risk-off markets could pressure the stock.
The path to value creation is clear, with upcoming catalysts including Phase 2/3 data for NTLA-2001 (ATTR), Phase 2 data for NTLA-2002 (HAE), FDA regulatory feedback, and potential commercial filings. While clinical setbacks, long-term safety issues, or competitive advances could severely impact the stock, the bull case is compelling: multiple approved drugs could validate the platform and drive a $20–30 billion market capitalization. Intellia offers a high-risk, high-reward proposition for investors willing to back a true biotech innovator poised to redefine treatment paradigms.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy’s commercial potential, early patient uptake, outcomes-based reimbursement, and a strong pipeline including in vivo liver editing. CRSP’s stock price has appreciated by approximately 30.63% since our coverage. Danny Green shares a similar view but emphasizes Intellia Therapeutics, Inc.’s (NTLA) in-vivo CRISPR work and optionality across monogenic diseases.
Intellia Therapeutics, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 31 hedge fund portfolios held NTLA at the end of the third quarter which was 33 in the previous quarter. While we acknowledge the risk and potential of NTLA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NTLA and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW
Disclosure: None.
